

# Efficacy of Platelet-Rich-Plasma (PRP) and Highly Purified Bovine Xenograft (Laddec®) Combination in Bone Regeneration after Cyst Enucleation: Radiological and Histological Evaluation

Sabrina Pappalardo<sup>1</sup>, Renzo Guarnieri<sup>2</sup>

<sup>1</sup>Department of Oral and Maxillofacial Surgery, Catania University, Catania, Italy.

<sup>2</sup>Freelance Researcher, S.C.S., Scientific Consulting Services, Rome, Italy.

## Corresponding Author:

Renzo Guarnieri

S.C.S., Scientific Consulting Services

Via Paolo Emiio 7, int 9

00144 Rome

Italy

Phone: (+39) 342-5224458

E-mail: [renzoguarnieri@gmail.com](mailto:renzoguarnieri@gmail.com)

## ABSTRACT

**Objectives:** The purpose of the present study was to evaluate the efficacy of adding platelet-rich plasma (PRP) to a new highly purified bovine allograft (Laddec®) in the bone regeneration of cystic bony defects augmented following cystectomy.

**Material and Methods:** Study sample included 20 patients undergoing cystectomy in which the bone defect was filled with PRP and Laddec®. All patients were examined with periapical radiographs before operation and at follow-up. After 3 months, at re-entry surgery for implant placement, bone core was taken for histological and histomorphometric analysis.

**Results:** The postoperative successive radiographs showed a good regeneration of bone in the height of bony defects with application of PRP to bone graft. By the first postoperative month, about 48% of the defect was filled, which gradually increased in each month and showed about 90% of defect-fill by 6 months. Histological and histomorphometric analysis, showed a significant presence of bone tissue and vessels, with newly formed bone in contact with anorganic bone particles. The mean volume of vital bone was  $68 \pm 1.6\%$  and the mean percentage of vital bone was  $48 \pm 2.4\%$ . The mean percentage of inorganic particles in tissues was  $20 \pm 1.2\%$  of the total volume. All the samples analyzed did not evidence the presence of inflammatory cells.

**Conclusions:** The results of this study showed how the use of Laddec® in association with platelet-rich plasma allows bone regeneration and has a potential for routine clinical use for regeneration of cystic bony defects.

**Keywords:** platelet-rich plasma; sintered bovine bone true bone ceramics; cystectomy; histology; xenograft.

Accepted for publication: 26 August 2013

### To cite this article:

Pappalardo S, Guarnieri R. Efficacy of Platelet-Rich-Plasma (PRP) and Highly Purified Bovine Xenograft (Laddec®) Combination in Bone Regeneration after Cyst Enucleation: Radiological and Histological Evaluation.

URL: <http://www.ejomr.org/JOMR/archives/2013/3/e3/v4n3e3ht.pdf>

doi: [10.5037/jomr.2013.4303](https://doi.org/10.5037/jomr.2013.4303)

## INTRODUCTION

Bone-replacement graft materials have played an important role in regenerative dentistry for many years. Several types of filling biomaterials have been evaluated for bone regeneration, and the choice of the biomaterial mostly depends on its features and application site [1]. The grafts could be classified according to their origin as autologous, homologous, heterologous and alloplastic materials [2,3], and according to their mechanism as osteogenic, osteoconductive, and osteoinductive materials [4]. Osteogenic materials directly stimulate bone cells to synthesize bone tissue; osteoconductive materials facilitate cell proliferation, migration and new bone apposition; osteoinductive materials induce differentiation of mesenchymal cells into osteoblasts [5].

Since 1978, autologous material has been used for bone regeneration and presently it is considered the gold standard in bone grafts since it has osteogenetic, osteoconductive and osteoinductive features [6,7]. The advantage of autogenous bone is that it maintains bone structures such as minerals and collagen, as well as viable osteoblasts and bone morphogenetic proteins (BMP); furthermore, there is no immunological response to autologous grafts [7]. Its main disadvantages are increased surgical time and patient morbidity [8].

Homologous grafts, are composed by non-vital osseous tissue taken from one individual, stocked in bone banks, and transferred to another individual of the same species [9]. There are three forms of homologous bone or allograft: fresh frozen, Freeze-Dried Bone Allograft (FDBA) and Demineralized Freeze-Dried Bone Allograft (DFDBA). Homologous graft is thought to be osteoinductive and osteoconductive [10], but the amount of BMPs in any single allograft has shown dramatic variability [11,12], and contradictory opinions about its biological properties are still present in literature [13-17].

Heterologous grafts consist of deproteinized cancellous skeletal bone tissue that is harvested from one species and transferred to the recipient site of another species; bovine bone being the most common source [9]. Heterologous materials have been used in several types of bone defects with satisfactory results; the advantage is the maintenance of the physical dimension, and the disadvantage is that they are only osteoconductive [18]. Alloplastic materials are synthetic materials that have been developed to replace human bone and that are available in different sizes, forms and textures. They are biocompatible and are the most common type of graft materials utilized [4]. The varying nature of commercially available synthetic graft materials,


such as porosity, geometries, different solubility, and densities, determines their biological features and their resorption times. There are several types of alloplastic substances in clinical use nowadays: calcium phosphate-based (CaPs), other ceramics (e.g. Hydroxyapatite - HA), Biphasic Calcium Phosphate (BCP), Tricalcium Phosphate (TCP), Calcium Sulfate, and Biocompatible Composite Polymers. Calcium phosphate cement composites (CPCs) are osteoconductive materials rapidly integrate into the bone structure and are transformed into new bone by the action of bone cells responsible for the local bone remodelling [19]. However, in spite of these good properties, synthetic materials have limitations due to their poor mechanical properties and slow biodegradation *in vivo* [20]. In view of the biological limitations associated individually with graft materials, surgeons have attempted to augment the activity and physical properties with composite grafts combining molecular, cellular, and genetic tissue engineering technologies [21-23]. The molecular approach using BMPs has received the most attention over the past decade. BMPs are differentiation factors that are part of the transforming growth factor superfamily [24], but many other factors also contribute, such as transforming growth factor (TGF- $\beta$ s), insuline-like growth factor (IGFs), fibroblast growth factor (FGFs), platelet-derived growth factor (PDGFs) [5]. The commercial availability of these growth factors (GF) has given oral and maxillofacial surgeons an additional option for the reconstruction of bony defects, but despite their potential usefulness, GF are still not available for routine use in practice. Another GF approach is to use the patient's own blood, separating out the platelet-rich plasma (PRP) and adding this concentrated group of autologous GFs to the grafting material [25]. PRP is considered to be a rich source of autologous GFs, and the contribution of PRP formulations to the bone healing process is thought to be based on the GFs contained [26]. The addition of PRP to autogenous grafts showed a more rapid and dense bone formation compared to autogenous grafts used alone for bone augmentation [25]. PRP has been also used in conjunction with allografts as a source of autologous GFs [27], but an improvement in bone formation when PRP is added to these graft materials has not been demonstrated clearly [28]. Recently has been proposed to surgeons an highly purified bovine allograft characterized by preservation of the type I collagen matrix associated with spindle-shaped hydroxyapatite crystals (Laddec<sup>®</sup>, BioHorizons, Birmingham, USA) [29,30]. The results of preliminary studies suggest that presence of type I collagen fibers in the matrix of a bone biomaterial could be of major interest to determine cell attachment, spreading

and orientation of osteoblasts and that type I collagen can bind osteoblasts via specific cell surface receptors, the integrins [31,32]. Hence, the present study was undertaken to assess the role of platelet rich plasma with this highly purified bovine allograft in regeneration of osseous defects of jaws caused by cysts enucleation.


**MATERIAL AND METHODS**

The present study included 20 consecutively treated patients, between 34 and 68 years of age, who needed cystectomy for some kind of pathology in the oral cavity (Figures 1 - 4). In all the patients, after cystectomy, PRP mixed with Laddec® was used for bone regeneration. Subjects with systemic diseases, renal disorders, regional malignancies, and respiratory problems were excluded from the study. All patients were examined with panoramic radiographs (Promax, Planmeca, Helsinki, Finland) converted into digital images using the computed system Regius (Konica, Minolta, Tokyo,


Japan). Periapical radiographs (Ultra-speedA, Eastman Kodak Co, Rochester NY, USA), by means of 65 kV dental X-ray unit equipped with a longcone (Oralix 65 S, Gendex Dental System S.r.l., Milano, Italy) were used before surgery for preoperative evaluation of size lesion, and at 1 month, 2 months, 4 months, and 6 months postsurgery, respectively, to assess the rate of bone regeneration. A silicone index material was fixated to the adjacent teeth, and a radiograph holder was constructed for each patient. This technique ensures that the same position of the radiograph could be reproduced at each visit. All these radiographs were compared with preoperative radiographs to check the height of bone regenerated (defect bone fill) from the base of the defect to cemento-enamel junction (CEJ) of the adjacent teeth. The nature of the study was explained to the patients and informed consent was obtained. The study was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki, The protocol and consent form were approved by the institutional ethics committee of University of Catania (Italy).



**Figure 1.** Example of radiographic cystic cavity shrinkage: A = preoperative, B = 6 months postoperative.



**Figure 3.** Intraoperative view: positioning of the PRP.



**Figure 2.** Intraoperative view: enucleation of the cyst.



**Figure 4.** Intraoperative view: positioning of PRP and Laddec®.

### PRP preparation

The PRP was performed at the Department of Hematology Hospital “Canizzaro” Catania. Prior to the start of the surgery, 300 ml of blood was drawn intravenously from patients and collected in sterile plastic vacuum tube coated with anti-coagulant citric acid and dextrose. Automated centrifugation machine was used for obtaining PRP with a speed of 1300 rpm for 10 min. After centrifugation, 3 layers were obtained: 1) an upper straw coloured fluid - PPP (Platelet Poor Plasma); 2) a middle buffy coat rich in platelets; 3) a lower layer rich in red blood cell (RBC). The straw coloured plasma was collected along with buffy coat and 1 ml of the RBC layer. This was centrifuged at 2000 rpm for 10 min. The PRP was obtained in the form of a red button at the bottom of the test tube. This was collected with the help of a pasture pipette and transferred into a sterile tube. The PPP was discarded. PRP obtained after second centrifugation was placed in a sterile tube. For activation, 6 ml of calcium chloride and thrombin were added to PRP. A first layer of PRP gel was introduced into the residual bone cavity after cystectomy to stimulate the capillary regeneration in wound healing [33], and a second layer was mixed with Laddec® in a volume preparation of 1:1.

### Histological and histomorphometric evaluation

3 months after surgery a bone biopsy was performed in all patients. Specimens were taken through the use of a milling cutter of 2.5 mm diameter trephine (Figure 5). The cylinder marrow was used for histological and histomorphometric analysis. The biopsies were immediately fixed in 4% formaldehyde in a buffered solution of 0.1 M phosphate (pH 7.3) at 4 °C for 24 hours to their dispatch to the laboratory. Samples were hydrated gradually with ethanol and soaked in Epon 812 (Shell Chemical Co., New York, NY, USA). Decalcified sections of a thickness of  $30 \pm 10 \mu\text{m}$  were obtained by cutting, by means of Buehler Isomet (Buehler, An ITW Co, Lake Bluff, IL, USA) along the vertical axis of the cylinder marrow. The bone sections were stained with toluidine blue and were used for qualitative histological analysis and for quantitative histomorphometric analysis, carried out with FOMI III (Carl Zeiss, Oberkochen, Germany) equipped with a microscope with image resolution (DC 280 Leica, Wetzlar, Germany).

### Statistical analysis

The height of regenerated bone (defect bone fill) in mm at four follow-up periods was compared with that




Figure 5. Re-entry surgery after 3 months.

from the preoperative periapical radiographs. The data set was analysed with the aid of the SPSS 13.0 package (SPSS, Chigaco, IL, USA) and a Student *t*-test was used for comparison between values of different time periods. Results were considered statistically significant at  $P < 0.05$ .

### RESULTS

In the periapical radiographs, it was observed that the mean preoperative defect size was 22.5 mm with standard deviation of  $\pm 4.5$  when calculated from the base of the defect to the CEJ of the adjacent tooth. In the first month, the defect size reduced to  $9.4 \pm 1.1$  mm, the difference from the preoperative radiograph was  $13.1 \pm 4.2$  mm, and the size of the defect was filled by 56%. In the second month the defect size reduced to  $8.4 \pm 0.6$  mm, the difference from the preoperative radiograph was  $14.1 \pm 4$  mm, and the size of the defect was filled by 62%. In the fourth month, the defect size reduced to  $4.7 \pm 1.5$  mm, the difference from the preoperative radiograph was  $17.8 \pm 4.4$  mm, and the size of the defect was filled by 74%. In the sixth month, the defect size reduced to  $1.1 \pm 2$  mm, the difference from the preoperative radiograph was  $21 \pm 4.5$  mm, and the size of the defect was filled by 92%. The difference was significant between the postoperative 4 months and 6 months results (Table 1).

The postoperative successive periapical radiographs showed adequate consolidation (regeneration) of the bone, as manifested by homogeneous radiopacity. On observation for comparison of height of regenerated bone, it was noticed that, by first postoperative month about 56% of the defect was filled; this gradually increased in each month and showed about 92% of defect fill at 6 months.

**Table 1.** Observation for the height of regenerated bone (defect bone fill) with platelet rich plasma + Laddec® application seen on periapical radiograph

Examination periods	Bony defect (mm) Mean ± SD	Difference operative defect size (mm) Mean ± SD	Defect bone fill (%)
Preoperative	22.5 ± 4.5		
1 <sup>st</sup> months postoperative	9.4 ± 1.1	13.1 ± 4.2	56
2 <sup>nd</sup> months postoperative	8.4 ± 0.6	14.1 ± 4	62
4 <sup>th</sup> months postoperative	4.7 ± 1.5	17.8 ± 4.4	74
6 <sup>th</sup> months postoperative	1.1 ± 2	21.4 ± 4.5	92

P < 0.05<sup>a</sup>


SD = standard deviation.

<sup>a</sup>The difference was significant between the post-operative 4 months and 6 months results.


In all the specimens, histological analysis showed a significant presence of bone tissue and vessels. Both, histological and histomorphometric analysis, showed newly formed bone in contact with anorganic bone particles. The mean volume of vital bone was 68 ± 1.6% and the mean percentage of vital bone was 48 ± 2.4%. The mean percentage of inorganic particles in tissues was 20 ± 1.2% of the total volume. All the samples analyzed did not evidence the presence of inflammatory cells (Figures 6 - 9).

**DISCUSSION**


Cystectomy includes the removal of all inflamed soft tissues and sometimes application of different biomaterials to enhance new bone formation in the defect site [34,35]. Various bone grafts and barrier membranes can be used to achieve optimal healing and regeneration of the cystic cavity. All these approaches are known as regenerative therapies. Recently it has been developed a procedure for bony defects regeneration utilizes PRP




**Figure 6.** Histological view of new bone and vascular proliferation. Toluidine blue stain, original magnification x40 (Courtesy of Dr. Roberto Crespi).



**Figure 7.** Histological view of lines of osteocytes. Toluidine blue stain, original magnification x120 (Courtesy of Dr. Roberto Crespi).



**Figure 8.** Increased cellular activity with lines of newly formed bone tissue. Toluidine blue stain, original magnification x40 (Courtesy of Dr. Roberto Crespi).



**Figure 9.** At high magnification it is possible to observe osteoblasts surrounding particles of graft material. Toluidine blue stain, original magnification x160 (Courtesy of Dr. Roberto Crespi).

in addition to bone grafts, and several studies have showed that a combination of PRP with bone grafts promote bone regeneration [36-42]. However, other authors still argue the lack of scientific evidence for defending the use of PRP associated with bone grafts in bone regeneration and recommend the surgeon to maintain a critical mind regarding its efficacy [43,44]. In our opinion, the controversy found in the literature regarding the use of this technique could be probably related to a lack of standardization in the different PRP formulations, and in the protocols, experimental models and surgical techniques employed.

Cystic cavity regeneration is a complex process involving both tissue repair and regeneration. The cellular events responsible for healing are controlled and regulated by specific signalling molecules, growth factors, and cytokines. TGF- $\beta$ 1, Bone morphogenetic protein-2 (BMP-2), and PDGF-A are secreted by cells recruited to the healing wound which are released in response to wounding stimuli detected at the cell surface [45,46]. The local availability of these growth factors is enhanced by about threefold or greater in concentration by addition of autologous PRP. It has been also reported that during the early stages of wound healing PRP has a strong stimulant effect on capillary regeneration [33]. Particularly, the publications, which point out positive features of PRP over the last years, have stressed:

1. Importance of controlled release systems of growth and differentiation factors using biomaterials in combination with PRP [47];
2. Enhancement of osteogenesis and angiogenesis [48];
3. Inhibition of osteoclast activation [49];
4. The enhancement of bone density adding PRP to a suboptimal dose of recombinant human BMP-2 (rhBMP-2) [30];
5. A significant increase of early bone marrow stromal cells (BMSCs) proliferation and differentiation using the combination of rhBMP-2 and bFGF (one of the signalling molecules of PRP) [50];
6. Relevance of PDGF and transforming growth factors (TGF- $\alpha$ 1 and TGF32) for bone regeneration [51].

Our study used these principles for enhancing the osteoconductive property of a new highly purified bovine allograft (Laddec<sup>®</sup>) by addition of autologous PRP in regeneration of osseous defects of jaws caused by cystectomy. Radiographic assessments of present study indicated that this association induced a fast new bone growth in the cystic cavities. It was observed that the defect was filled by 56% at the first month, and after a time interval of 6 months postoperatively the defect was filled by 92%, showing a significant increase in vertical height on radiographs. The clinical efficacy of

the association PRP and Laddec<sup>®</sup> reported from our study is also supported by histological data that we have documented, since the mean volume of vital bone at 6 months was found to be  $68 \pm 1.6\%$  and the mean percentage of vital bone  $48 \pm 2.4\%$ . These data are in accordance with and in support of what has been previously suggested by others studies that have shown that adding PRP to graft material significantly accelerates the rate of bone formation and improves trabecular bone density as compared to sites treated with only graft material [25,52]. Contrary to this, there are also reports that suggest that the use of PRP in combination with anorganic bovine bone mineral does not benefit bone regeneration [53-60], highlighted that osteoblasts have difficulties in adhering to allograft smooth surfaces. Since some allograft has a smooth surface [61,62], most attempts of creating new bone using bovine allografts may not be able to provide close contact between bone and the bovine material under reproducible conditions. Baslè and co-workers [31] suggested that treatments applied to bovine allografts to prevent immunological, inflammatory, bacteriological or virological adverse responses, may also interact with type I collagen, to which can bind osteoblasts via specific cell surface receptors, the integrins. The authors have compared *in vitro* two different bovine allografts that displayed similar architectural organization with connected plates and rods and similar surface topography and roughness. They differed by the presence or not of collagen type I. The first one was characterized by preservation of the type I collagen matrix associated with spindle-shaped hydroxyapatite crystals and the second was solely composed by heat-modified apatite crystals. Osteoblast-like cells (Saos-2) were cultured on both biomaterials and examined in scanning and transmission electron microscopy after 7 and 14 days. Both biomaterials were cytocompatible as demonstrated by good ultrastructural cell preservation. At the surface of the collagen containing biomaterial, cells were elongated in shape and oriented according to the trabecular architecture and to the superficial collagen network. After 14 days of culture, cells were confluent and the biomaterial surface was hidden by the cell sheet. The beta 1 integrin subunit was detected by immunogold in transmission electron microscopy in close relationship with the superficial collagen fibers of the biomaterial and with the outer cell surface. When cultures were carried out in presence of anti beta 1 integrin subunit, cells were packed and piled up with lack of specific orientation. At the surface of the deproteinized biomaterial, cells were globular without specific disposition and often partially attached to the surface. After 14 days of culture, large areas of the biomaterial surface remained uncovered. Anti beta 1 subunits conjugated with gold particles

were detected around the cells but with no specific association with the deproteinized biomaterial. These results strongly suggest that the chemical nature of the surface of bovine allografts directly influences adhesion process, shape, and spatial organization of cultured osteoblastic cells. Furthermore, the presence of type I collagen fibers in the matrix seems to be of major interest to determine cell attachment, spreading and orientation via interaction between type I collagen and beta 1 integrin subunit of osteoblasts. In contrast, at the surface of the single mineral matrix, cells were round shaped with random disposition. This data has been also confirmed by another research [33] in which has been documented that the beta 1-integrin subunit was localized at the outer surface of cells, in close association with collagen and at the contact points between cells and Laddec® allograft. These *in vitro* results are still limited and must be confirmed by other studies, but they could support favourable outcomes concerning newly grown bone achieved in our present clinical study performed using a combination of PRP and Laddec®. We have to add that it is not possible to compare the published clinical studies and animal trials concerning the association between PRP and heterologous grafts, due to the varying methodologies applied and due to the varying nature and biological features of commercially available bovine graft materials. The results of our clinical and histological study seems however to confirm that preservation of

the type I collagen matrix associated with spindle-shaped hydroxapatite crystals in bovine graft bone substitutes may promote the biomaterial-PRP interaction. Within the limits of this study, the treatment with a combination of PRP and Laddec® bovine graft seems to lead to significantly favourable and fast bone regeneration after grafting enucleated mandibular cyst cavities, however further studies are necessary to assess the long-term effectiveness of PRP-Laddec® association, and a larger sample size is recommended.

## CONCLUSIONS

The results of this study showed that Laddec® in association with platelet rich plasma has a potential for routine clinical use for regeneration of cystic bony defects.

## ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS

The authors report no conflicts of interest related to this study. The authors would like to thank Dr. Roberto Crespi (Ateneo Vita Salute San Raffaele, Milano, Italy) for histological and histomorphometric analysis.

## REFERENCES

1. McAllister BS, Haghghat K. Bone augmentation techniques. *J Periodontol.* 2007 Mar;78(3):377-96. Review. [Medline: [17335361](#)] [doi: [10.1902/jop.2007.060048](#)]
2. Garofalo GS. Autogenous, allogenic and xenogenic grafts for maxillary sinus elevation: literature review, current status and prospects. *Minerva Stomatol.* 2007 Jul-Aug;56(7-8):373-92. Review. [Medline: [17912196](#)]
3. Rodella LF, Favero G, Labanca M. Biomaterials in maxillofacial surgery: membranes and grafts. *Int J Biomed Sci.* 2011 Jun;7(2):81-8. [Medline: [23675225](#)] [[FREE Full Text](#)]
4. Kao ST, Scott DD. A review of bone substitutes. *Oral Maxillofac Surg Clin North Am.* 2007 Nov;19(4):513-21, vi. Review. [Medline: [18088902](#)] [doi: [10.1016/j.coms.2007.06.002](#)]
5. Muschler GF, Lane JM. Spine fusion: Principles of Bone Fusion. In: Herkowitz HN, Garfin SR, Balderston RA, editors. *The Spine.* Philadelphia: WB Saunders; 1999. p. 1573-89.
6. Burchardt H. The biology of bone graft repair. *Clin Orthop Relat Res.* 1983 Apr;(174):28-42. [Medline: [6339139](#)]
7. Urist MR. Bone: formation by autoinduction. *Science.* 1965 Nov 12;150(3698):893-9. [Medline: [5319761](#)] [doi: [10.1126/science.150.3698.893](#)]
8. AlGhamdi AS, Shibly O, Ciancio SG. Osseous grafting part II: xenografts and alloplasts for periodontal regeneration--a literature review. *J Int Acad Periodontol.* 2010 Apr;12(2):39-44. Review. [Medline: [20465030](#)]
9. Stevenson S. Biology of bone grafts. *Orthop Clin North Am.* 1999 Oct;30(4):543-52. Review. [Medline: [10471759](#)] [doi: [10.1016/S0030-5898\(05\)70107-33](#)]
10. Boyan BD, Ranly DM, Schwartz Z. Use of growth factors to modify osteoinductivity of demineralized bone allografts: lessons for tissue engineering of bone. *Dent Clin North Am.* 2006 Apr;50(2):217-28, viii. [Medline: [16530059](#)] [doi: [10.1016/j.cden.2005.11.007](#)]
11. Minichetti JC, D'Amore JC, Hong AY, Cleveland DB. Human histologic analysis of mineralized bone allograft (Puros) placement before implant surgery. *J Oral Implantol.* 2004;30(2):74-82. [Medline: [15119456](#)] [doi: [10.1563/0.693.1](#)]

12. Schwartz Z, Somers A, Mellonig JT, Carnes DL Jr, Wozney JM, Dean DD, Cochran DL, Boyan BD. Addition of human recombinant bone morphogenetic protein-2 to inactive commercial human demineralized freeze-dried bone allograft makes an effective composite bone inductive implant material. *J Periodontol*. 1998 Dec;69(12):1337-45. [Medline: [9926763](#)] [doi: [10.1902/jop.1998.69.12.1337](#)]
13. Becker W, Schenk R, Higuchi K, Lekholm U, Becker BE. Variations in bone regeneration adjacent to implants augmented with barrier membranes alone or with demineralized freeze-dried bone or autologous grafts: a study in dogs. *Int J Oral Maxillofac Implants*. 1995 Mar-Apr;10(2):143-54. [Medline: [7744433](#)]
14. Frost DE, Fonseca RJ, Burkes EJ Jr. Healing of interpositional allogeneic lyophilized bone grafts following total maxillary osteotomy. *J Oral Maxillofac Surg*. 1982 Dec;40(12):776-86. [Medline: [6754893](#)]
15. Kübler N, Reuther J, Kirchner T, Priessnitz B, Sebald W. Osteoinductive, morphologic, and biomechanical properties of autolyzed, antigen-extracted, allogeneic human bone. *J Oral Maxillofac Surg*. 1993 Dec;51(12):1346-57. [Medline: [8229415](#)] [doi: [10.1016/S0278-2391\(10\)80141-7](#)]
16. Wetzel AC, Stich H, Caffesse RG. Bone apposition onto oral implants in the sinus area filled with different grafting materials. A histological study in beagle dogs. *Clin Oral Implants Res*. 1995 Sep;6(3):155-63. [Medline: [7578791](#)] [doi: [10.1034/j.1600-0501.1995.060304.x](#)]
17. Whittaker JM, James RA, Lozada J, Cordova C, GaRey DJ. Histological response and clinical evaluation of heterograft and allograft materials in the elevation of the maxillary sinus for the preparation of endosteal dental implant sites. Simultaneous sinus elevation and root form implantation: an eight-month autopsy report. *J Oral Implantol*. 1989;15(2):141-4. [Medline: [2561759](#)]
18. Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. *Clin Orthop Relat Res*. 2000 Feb;(371):10-27. Review. [Medline: [10693546](#)] [doi: [10.1097/00003086-200002000-00003](#)]
19. Zhang Y, Xu HH, Takagi S, Chow LC. In-situ hardening hydroxyapatite-based scaffold for bone repair. *J Mater Sci Mater Med*. 2006 May;17(5):437-45. [Medline: [16688584](#)] [doi: [10.1007/s10856-006-8471-z](#)]
20. Julien M, Khairoun I, LeGeros RZ, Delplace S, Pilet P, Weiss P, Daculsi G, Bouler JM, Guicheux J. Physico-chemical-mechanical and in vitro biological properties of calcium phosphate cements with doped amorphous calcium phosphates. *Biomaterials*. 2007 Feb;28(6):956-65. Epub 2006 Nov 22. [Medline: [17123598](#)] [doi: [10.1016/j.biomaterials.2006.10.018](#)]
21. Boyne PJ, Nath R, Nakamura A. Human recombinant BMP-2 in osseous reconstruction of simulated cleft palate defects. *Br J Oral Maxillofac Surg*. 1998 Apr;36(2):84-90. [Medline: [9643591](#)] [doi: [10.1016/S0266-4356\(98\)90173-5](#)]
22. Howell TH, Fiorellini J, Jones A, Alder M, Nummikoski P, Lazaro M, Lilly L, Cochran D. A feasibility study evaluating rhBMP-2/absorbable collagen sponge device for local alveolar ridge preservation or augmentation. *Int J Periodontics Restorative Dent*. 1997 Apr;17(2):124-39. [Medline: [9497707](#)]
23. Margolin MD, Cogan AG, Taylor M, Buck D, McAllister TN, Toth C, McAllister BS. Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. *J Periodontol*. 1998 Aug;69(8):911-9. [Medline: [9736374](#)] [doi: [10.1902/jop.1998.69.8.911](#)]
24. Schmitt JM, Hwang K, Winn SR, Hollinger JO. Bone morphogenetic proteins: an update on basic biology and clinical relevance. *J Orthop Res*. 1999 Mar;17(2):269-78. Review. [Medline: [10221845](#)] [doi: [10.1002/jor.1100170217](#)]
25. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998 Jun;85(6):638-46. [Medline: [9638695](#)] [doi: [10.1016/S1079-2104\(98\)90029-4](#)]
26. Borzini P, Mazzucco L. Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point? *ISBT Science Series*. 2007 Jul;2(1): 272-81. [doi: [10.1111/j.1751-2824.2007.00085.x](#)]
27. Landesberg R, Moses M, Karpatkin M. Risks of using platelet rich plasma gel. *J Oral Maxillofac Surg*. 1998 Sep;56(9):1116-7. [Medline: [9734779](#)] [doi: [10.1016/S0278-2391\(98\)90286-5](#)]
28. Sánchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. *Int J Oral Maxillofac Implants*. 2003 Jan-Feb;18(1):93-103. [Medline: [12608674](#)]
29. Chappard D, Zhioua A, Grizon F, Basle MF, Rebel A. [Biomaterials for bone filling: comparisons between autograft, hydroxyapatite and one highly purified bovine xenograft]. *Bull Assoc Anat (Nancy)*. 1993 Dec;77(239):59-65. French. [Medline: [8025339](#)]
30. Poumarat G, Squire P. Comparison of mechanical properties of human, bovine bone and a new processed bone xenograft. *Biomaterials*. 1993 Apr;14(5):337-40. [Medline: [8507776](#)] [doi: [10.1016/0142-9612\(93\)90051-3](#)]
31. Baslé MF, Grizon F, Pascaretti C, Lesourd M, Chappard D. Shape and orientation of osteoblast-like cells (Saos-2) are influenced by collagen fibers in xenogenic bone biomaterial. *J Biomed Mater Res*. 1998 Jun 5;40(3):350-7. [Medline: [9570064](#)] [doi: [10.1002/\(SICI\)1097-4636\(19980605\)40:3<350::AID-JBM2>3.0.CO;2-E](#)]
32. Baslé MF, Lesourd M, Grizon F, Pascaretti C, Chappard D. [Type I collagen in xenogenic bone material regulates attachment and spreading of osteoblasts over the beta1 integrin subunit]. *Orthopade*. 1998 Feb;27(2):136-42. German. [Medline: [9530670](#)] [doi: [10.1007/PL00003479](#)]
33. Lindeboom JA, Mathura KR, Aartman IH, Kroon FH, Milstein DM, Ince C. Influence of the application of platelet-enriched plasma in oral mucosal wound healing. *Clin Oral Implants Res*. 2007 Feb;18(1):133-9. [Medline: [17224034](#)] [doi: [10.1111/j.1600-0501.2006.01288.x](#)]

34. Ettl T, Gosau M, Sader R, Reichert TE. Jaw cysts - filling or no filling after enucleation? A review. *J Craniomaxillofac Surg*. 2012 Sep;40(6):485-93. Epub 2011 Sep 3. Review. [Medline: [21890372](#)] [doi: [10.1016/j.jcms.2011.07.023](#)]
35. Pradel W, Eckelt U, Lauer G. Bone regeneration after enucleation of mandibular cysts: comparing autogenous grafts from tissue-engineered bone and iliac bone. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2006 Mar;101(3):285-90. Epub 2006 Jan 19. [Medline: [16504859](#)] [doi: [10.1016/j.tripleo.2005.06.001](#)]
36. Camargo PM, Lekovic V, Weinlaender M, Vasilic N, Madzarevic M, Kenney EB. Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. *J Periodontal Res*. 2002 Aug;37(4):300-6. [Medline: [12200975](#)] [doi: [10.1034/j.1600-0765.2002.01001.x](#)]
37. Choi BH, Zhu SJ, Kim BY, Huh JY, Lee SH, Jung JH. Effect of platelet-rich plasma (PRP) concentration on the viability and proliferation of alveolar bone cells: an in vitro study. *Int J Oral Maxillofac Surg*. 2005 Jun;34(4):420-4. Epub 2005 Jan 27. [Medline: [12200975](#)] [doi: [10.1016/j.ijom.2004.10.018](#)]
38. Froum SJ, Wallace SS, Tarnow DP, Cho SC. Effect of platelet-rich plasma on bone growth and osseointegration in human maxillary sinus grafts: three bilateral case reports. *Int J Periodontics Restorative Dent*. 2002 Feb;22(1):45-53. [Medline: [11922217](#)]
39. Kassolis JD, Reynolds MA. Evaluation of the adjunctive benefits of platelet-rich plasma in subantral sinus augmentation. *J Craniofac Surg*. 2005 Mar;16(2):280-7. [Medline: [15750426](#)]
40. Ojima Y, Mizuno M, Kuboki Y, Komori T. In vitro effect of platelet-derived growth factor-BB on collagen synthesis and proliferation of human periodontal ligament cells. *Oral Dis*. 2003 May;9(3):144-51. [Medline: [12945596](#)] [doi: [10.1034/j.1601-0825.2003.02906.x](#)]
41. Sammartino G, Tia M, Marenzi G, di Lauro AE, D'Agostino E, Claudio PP. Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. *J Oral Maxillofac Surg*. 2005 Jun;63(6):766-70. [Medline: [15944972](#)] [doi: [10.1016/j.joms.2005.02.010](#)]
42. Shanaman R, Filstein MR, Danesh-Meyer MJ. Localized ridge augmentation using GBR and platelet-rich plasma: case reports. *Int J Periodontics Restorative Dent*. 2001 Aug;21(4):345-55. [Medline: [11519703](#)]
43. Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. *Tissue Eng Part B Rev*. 2008 Sep;14(3):249-58. Review. [Medline: [18601587](#)] [doi: [10.1089/ten.teb.2008.0062](#)]
44. Plachokova AS, Nikolidakis D, Mulder J, Jansen JA, Creugers NH. Effect of platelet-rich plasma on bone regeneration in dentistry: a systematic review. *Clin Oral Implants Res*. 2008 Jun;19(6):539-45. Epub 2008 Apr 16. Review. [Medline: [18422984](#)] [doi: [10.1111/j.1600-0501.2008.01525.x](#)]
45. Grageda E. Platelet-rich plasma and bone graft materials: a review and a standardized research protocol. *Implant Dent*. 2004 Dec;13(4):301-9. Review. [Medline: [15591991](#)]
46. Pierce GF, Vande Berg J, Rudolph R, Tarpley J, Mustoe TA. Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. *Am J Pathol*. 1991 Mar;138(3):629-46. [Medline: [2000940](#)] [[FREE Full Text](#)]
47. Bertoldi C, Pinti M, Zaffè D, Cossarizza A, Consolo U, Ceccherelli GB. Morphologic, histochemical, and functional analysis of platelet-rich plasma activity on skeletal cultured cells. *Transfusion*. 2009 Aug;49(8):1728-37. [Medline: [19413738](#)] [doi: [10.1111/j.1537-2995.2009.02190.x](#)]
48. Hu ZM, Peel SA, Ho SK, Sándor GK, Clokie CM. Comparison of platelet-rich plasma, bovine BMP, and rhBMP-4 on bone matrix protein expression in vitro. *Growth Factors*. 2009 Oct;27(5):280-8. [Medline: [19637071](#)] [doi: [10.1080/08977190903137819](#)]
49. Cenni E, Avnet S, Fotia C, Salerno M, Baldini N. Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood. *J Orthop Res*. 2010 Jun;28(6):792-7. [Medline: [20058277](#)]
50. Wang L, Huang Y, Pan K, Jiang X, Liu C. Osteogenic responses to different concentrations/ratios of BMP-2 and bFGF in bone formation. *Ann Biomed Eng*. 2010 Jan;38(1):77-87. Epub 2009 Nov 17. [Medline: [19921434](#)] [doi: [10.1007/s10439-009-9841-8](#)]
51. Graham S, Leonidou A, Lester M, Heliotis M, Mantalaris A, Tsiridis E. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. *Expert Opin Investig Drugs*. 2009 Nov;18(11):1633-54. Review. [Medline: [19747084](#)] [doi: [10.1517/13543780903241607](#)]
52. Garg AK, Gargene D, Peace I. Using platelet-rich plasma to develop an autologous membrane for growth factor delivery in dental implant therapy. *Dent Implantol Update*. 2000 Jun;11(6):41-4. [Medline: [12851972](#)]
53. Aghaloo TL, Moy PK, Freymiller EG. Investigation of platelet-rich plasma in rabbit cranial defects: A pilot study. *J Oral Maxillofac Surg*. 2002 Oct;60(10):1176-81. [Medline: [12378494](#)] [doi: [10.1053/joms.2002.34994](#)]
54. Fan Z, Jia S, Su JS. [Influence of surface roughness of titanium implant on core binding factor alpha 1 subunit of osteoblasts]. *Zhonghua Kou Qiang Yi Xue Za Zhi*. 2010 Aug;45(8):466-70. Chinese. [Medline: [21122362](#)]
55. Farrell B, Block MS, Boudrwaux D, Stover J. Effect of PRP with and without membranes on bone defect healing. *J Oral Maxillofac Surg*. 2002;60(8):38.
56. Graziano A, d'Aquino R, Cusella-De Angelis MG, Laino G, Piattelli A, Pacifici M, De Rosa A, Papaccio G. Concave pit-containing scaffold surfaces improve stem cell-derived osteoblast performance and lead to significant bone tissue formation. *PLoS One*. 2007 Jun 6;2(6):e496. [Medline: [17551577](#)] [doi: [10.1371/journal.pone.0000496](#)] [[FREE Full Text](#)]

57. Kim EJ, Boehm CA, Fleischman AJ, Muschler GF, Kostov YV, Roy S. Modulating human connective tissue progenitor cell behavior on cellulose acetate scaffolds by surface microtextures. *J Biomed Mater Res A*. 2009 Sep 15;90(4):1198-205. [Medline: [18680188](#)] [doi: [10.1002/jbm.a.32160](#)]
58. Le Guehennec L, Lopez-Heredia MA, Enkel B, Weiss P, Amouriq Y, Layrolle P. Osteoblastic cell behaviour on different titanium implant surfaces. *Acta Biomater*. 2008 May;4(3):535-43. Epub 2007 Dec 10. [Medline: [18226985](#)] [doi: [10.1016/j.actbio.2007.12.002](#)]
59. Mata A, Kim EJ, Boehm CA, Fleischman AJ, Muschler GF, Roy S. A three-dimensional scaffold with precise micro-architecture and surface micro-textures. *Biomaterials*. 2009 Sep;30(27):4610-7. Epub 2009 Jun 12. [Medline: [19524292](#)] [doi: [10.1016/j.biomaterials.2009.05.023](#)] [[FREE Full Text](#)]
60. Mooren RE, Dankers AC, Merckx MA, Bronkhorst EM, Jansen JA, Stoelinga PJ. The effect of platelet-rich plasma on early and late bone healing using a mixture of particulate autogenous cancellous bone and Bio-Oss: an experimental study in goats. *Int J Oral Maxillofac Surg*. 2010 Apr;39(4):371-8. Epub 2010 Feb 2. [Medline: [20129756](#)] [doi: [10.1016/j.ijom.2009.12.019](#)]
61. Asti A, Visai L, Dorati R, Conti B, Saino E, Sbarra S, Gastaldi G, Benazzo F. Improved cell growth by Bio-Oss/PLA scaffolds for use as a bone substitute. *Technol Health Care*. 2008;16(6):401-13 [Medline: [19212036](#)]
62. Herten M, Rothamel D, Schwarz F, Friesen K, Koegler G, Becker J. Surface- and nonsurface-dependent in vitro effects of bone substitutes on cell viability. *Clin Oral Investig*. 2009 Jun;13(2):149-55. Epub 2008 Aug 8. [Medline: [18688661](#)] [doi: [10.1007/s00784-008-0214-8](#)]

**To cite this article:**

Pappalardo S, Guarnieri R. Efficacy of Platelet-Rich-Plasma (PRP) and Highly Purified Bovine Xenograft (Laddec®) Combination in Bone Regeneration after Cyst Enucleation: Radiological and Histological Evaluation. *J Oral Maxillofac Res* 2013;4(3):e3  
URL: <http://www.ejomr.org/JOMR/archives/2013/3/e3/v4n3e3ht.pdf>  
doi: [10.5037/jomr.2013.4303](#)

**Copyright** © Pappalardo S, Guarnieri R. Published in the JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH (<http://www.ejomr.org>), 1 October 2013.

This is an open-access article, first published in the JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH, distributed under the terms of the [Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License](#), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work and is properly cited. The copyright, license information and link to the original publication on (<http://www.ejomr.org>) must be included.